New birth control implant shows promise in early safety trial
NCT ID NCT05174884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new contraceptive implant called Casea S in 20 healthy women. The goal is to check how the body processes the hormone, how easy it is to remove, and if it's safe. The implant aims to prevent pregnancy for at least 78 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
20 people
The number who actually took part.
- Started
-
Dec 2023
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participants may be included in the study if they meet all of the following criteria: * willing and able to provide signed informed consent * female between 18 to 45 years of age (inclusive) * healthy based on results of medical evaluation including medical history, vital signs, and physical exam * has regular menstrual cycle (21 to 35 days) * not at risk for pregnancy (i.e., sterilized) * has a Body Mass Index (BMI) of 18 to 29.9 * provides normal mammogram results within the last year before enrollment for women 40 or older * is willing and able to comply with all study requirements and return to the investigational site for the follow-up procedures and assessments as specified in this protocol * Part 2 participants only: has daily access to a smartphone, tablet, or computer with internet access. Exclusion Criteria: Participants will be excluded from participating in this study if they meet any of the following criteria: * has multiple risk factors for cardiovascular disease (e.g., smoking, diabetes, obesity, hypertension, high LDL (low density lipoprotein), or high triglyceride levels) * has current or history of ischemic heart disease or cerebrovascular disease * has current or previous thromboembolic disorders * has systemic lupus erythematosus * has rheumatoid arthritis on immunosuppressive therapy * has migraine with aura * has undiagnosed abnormal vaginal bleeding * has known or suspected breast cancer, history of breast cancer or other progestin-sensitive cancer * has current or history of cervical cancer * has cirrhosis, liver tumors (benign or malignant), or active liver disease * has one or more baseline liver function test(s) above the local laboratory's normal range * has a hemoglobin \<10.5 g/dL * has used any injectable contraceptive in the past 6 months * has used any of the following medications within 4 weeks before enrollment: * any investigational drug * prohibited drugs (listed in Section 6.3.3.4.4.1 of the study protocol) * oral contraceptives, contraceptive ring, or patch * levonorgestrel intrauterine device (LNG IUD) or contraceptive implant * is pregnant * is currently breastfeeding * desires to become pregnant in the subsequent 30 months * has been pregnant in last 3 months * is using or planning to use prohibited drugs for their intended study duration * has abnormal cervical cytology requiring treatment * has known sensitivity to ENG * plans to move to another location in the next 30 months * is participating in any other clinical trial with a biomedical intervention * has any condition (social or medical), that in the opinion of the site investigator would make study participation unsafe, would interfere with adherence to the clinical study requirements, or complicate data interpretation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Contraception are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Profamilia
Santo Domingo, DN, 10401, Dominican Republic
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Watching the IUD go in: can a camera make contraception safer?
- Patch tested to block pregnancy
- Can a polymer block tubes without surgery? a trial investigates
- Can a redesigned IUD inserter make birth control safer and easier?
- Texts and local mentors: a new way to empower teen girls on contraception?
- Could a single implant replace the morning-after pill?